CA125 response: Can it replace the traditional response criteria in ovarian cancer?

Oncologist

Volumn 7, Issue 5, 2002, Pages 437-443

  Guppy, A E ^a   Rustin, G J S ^a,b  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

^b Mount Vermon Centre for Cancer Treatment   (United Kingdom)

Author keywords

CA125; Ovarian cancer; Response criteria

Indexed keywords

ALTRETAMINE; CA 125 ANTIGEN; CALCITRIOL; DOCETAXEL; ETOPOSIDE; GEMCITABINE; ISOTRETINOIN; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; RALTITREXED; TOPOTECAN;

ARTICLE; CANCER DIAGNOSIS; CANCER RESEARCH; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG EFFICACY; FOLLOW UP; HUMAN; OVARY CANCER; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RELIABILITY; TREATMENT OUTCOME;

CA-125 ANTIGEN; CLINICAL TRIALS; DISEASE PROGRESSION; FEMALE; HUMANS; MONITORING, PHYSIOLOGIC; OVARIAN NEOPLASMS; PATIENT CARE PLANNING; PREDICTIVE VALUE OF TESTS; RECURRENCE; RESEARCH DESIGN; TUMOR MARKERS, BIOLOGICAL;

EID: 0036409129     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.7-5-437     Document Type: Article

References (31)

1. Bast Jr RC, Feeney M, Lazarus H et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331-1337.
2. Bast Jr RC, Klug TL, St John E et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-887.
3. Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: Identification as a new mucin, MUC16. J Biol Chem 2001;276:27371-27375.
4. O'Brien TJ, Beard JB, Underwood LJ et al. The CA 125 gene: An extracellular superstructure dominated by repeat sequences. Tumour Biol 2001;22:348-366.
5. Tuxen MK, Soletormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev 1995;21:215-245.
6. van der Burg ME, Lammes FB, Verweij J. The role of CA125 in the early diagnosis of progressive disease in ovarian cancer. Ann Oncol 1990;1:301-302.
7. Rustin GJ, Nelstrop A, Stilwell J et al. Savings obtained by CA-125 measurements during therapy for ovarian carcinoma. The North Thames Ovary Group. Eur J Cancer 1992;28:79-82.
8. Talbot R. Temporary elevation of CA125 after abdominal surgical treatment for benign disease and cancer. Surg Gynaecol Obstet 1989;168:407-412.
9. Rustin GJ, Nelstrop AE, Tuxen MK et al. Defining progression of ovarian carcinoma during follow-up according to CA 125: A North Thames Ovary Group Study. Ann Oncol 1996;7:361-364.
10. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients. Ann Oncol 1997;8:963-968.
11. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.
12. Krebs HB, Goplerud DR, Kilpatrick SJ et al. Role of CA 125 as tumor marker in ovarian cancer. Obstet Gynecol 1986;67:473-477.
13. Rustin GJ, Nelstrop AE, McClean P et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996;14:1545-1551.
14. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216.
15. WHO Handbook for Reporting Results of Cancer Treatment. World Health Organization Offset Publication No 48. Geneva: World Health Organization, 1979.
16. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981;47:207-214.
17. Markman M. A proposal to use CA-125 to evaluate activity of new antineoplastic agents in ovarian cancer. Gynecol Oncol 1993;51:297-298.
18. Ng LW, Homesley HD, Barrett RJ et al. CA125 values predictive of clinical response during second-line chemotherapy for epithelial ovarian cancer. Am J Clin Oncol 1989;12:106-109.
19. Rustin GJ, van der Burg ME, Berek JS. Advanced ovarian cancer. Tumor markers. Ann Oncol 1993;4(suppl 4):71-77.
20. Lambert HE, Rustin GJ, Gregory WM et al. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. Ann Oncol 1997;8;327-333.
21. Rustin GJS, Nelstrop AE, Bentzen SM et al. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J Clin Oncol 2000;18:1733-1739.
22. Guastalla JP, Vincent P, Le Rol A et al. CA125 evaluation of chemotherapy response in patients with recurrent ovarian cancer: Rustin criteria revisited. Proc Am Soc Clin Oncol 2002;21:204a.
23. Davelaar EM, Bonfer JMG, Verstraeten RA et al. CA 125: A valid marker in ovarian carcinoma patients treated with paclitaxel. Cancer 1996;78:118-127.
24. Pearl ML, Yashar CM, Johnstone CM et al. Exponential regression of CA 125 during salvage treatment for ovarian cancer with taxol. Gynecol Oncol 1994;53:339-343.
25. Bridgewater JA, Nelstrop AE, Rustin GJS et al. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol 1999;17:501-508.
26. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12:2654-2666.
27. Vergote I, Rustin GJS, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 2000;92:1534-1535.
28. Rustin GJS, Marples M, Nelstrop AE et al. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 2001;19:4054-4057.
29. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst 2000;92:699-708.
30. Rustin GJS, Nelstrop AE, Crawford M et al. Phase II trial of oral altretamine for relapsed ovarian carcinoma: Evaluation of defining response by serum CA125. J Clin Oncol 1997;15:172-176.
31. Meyer T, Nelstrop AE, Mahmoudi M et al. Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer. Ann Oncol 2001;12:1705-1709.